HIV-1 vaccine development has been stymied by an inability to induce broadly reactive
neutralizing antibodies to the envelope (Env) trimer, the sole viral antigen on the virion …

Antibodies have been used for more than 100 years in the therapy of infectious diseases,
but a new generation of highly potent and/or broadly cross-reactive human monoclonal …

A central goal of HIV-1 vaccine research is the elicitation of antibodies capable of
neutralizing diverse primary isolates of HIV-1. Here we show that focusing the immune …

Abs are immune system proteins that recognize noxious molecules for elimination. Their
sequence diversity and binding versatility have made Abs the primary class of …

Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global
viruses, are a major focus of HIV vaccine design, with data from animal studies confirming …

Densely arranged N-linked glycans shield the HIV-1 envelope (Env) trimer from antibody
recognition. Strain-specific breaches in this shield (glycan holes) can be targets of vaccine …

Characterization of single antibody lineages within infected individuals has provided
insights into the development of Env-specific antibodies. However, a systems-level …

Recombination in HIV-1 is well documented, but its importance in the low-diversity setting of
within-host diversification is less understood. Here we develop a novel computational tool …

Interactions between the Fc segment of IgG and its receptors (FcγRs) found on cells such as
natural killer cells, monocytes, macrophages and neutrophils can potentially mediate …

Highlights•A neutralizing antibody-based vaccine is needed to curb the global HIV
pandemic.•Current vaccine approaches target unique features of bnAb precursors.• …